Solid Cancers
39
9
10
20
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.7%
3 terminated out of 39 trials
87.0%
+0.5% vs benchmark
0%
0 trials in Phase 3/4
25%
5 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (39)
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
An Antibody-armored Dendritic Cell in Patients With Solid Tumors
Predicting Reactions and Effects of Drugs Immunotherapy and Complications Through Oncosafety (PREDICTO Clinical Study)
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage Cancer
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
xDRIVE for Florida-based Cancer Patients
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
Serum IGF-1 and IGF-1Ec in Malignancy Assessment
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
A Study to Evaluate the Safety and Tolerability of EP0089
Real-life Performance Evaluation of the LiFlow X-ray Platform
Application of the sG8 Scale in Real-World Geriatric Oncology Patients
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study
A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors